Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

All absentee ballots must be submitted by 5 p.m. on May 20. The district also used the board meeting to celebrate its Regeneron Science Talent Search finalist, Sandeep Sawhney, and to recognize ...

Credit: kirisa99 via Getty Images. US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory ...

Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment. Targeted Therapies in Oncology: How has ...

Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...

Weave (NYSE: WEAV), a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses, today announced an integration with Practice Fusion, a ...

For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: + 46 (0) 8 510 530 00 [email protected] hellocare.ai, a leader in AI-assisted ...

Linvoseltamab is a bispecific antibody targeting B-cell maturation antigen ... to address therapeutic challenges and improve patient outcomes. The FDA accepted Regeneron’s BLA resubmission for ...

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and ...